Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
暂无分享,去创建一个
T. Delozier | M. Campone | T. Petit | F. Bidard | J. Pierga | P. Viens | T. Bachelot | E. Charafe-Jauffret | J. Gligorov | J. Ferrero | F. Lerebours | H. Roché | S. Kraemer | M. Pavlyuk